

# Texas Department of State Health Services

# Vaccine Updates

Saroj Rai, PhD, MPH



# DISCLAIMER

The information presented today is based on CDC's recent guidance and MAY change.

**December 7, 2020** 

#### **Evolving Landscape for COVID-19 Vaccine**

#### **Key Assumptions for COVID-19 Vaccine**







Limited doses may be available in December 2020, but supply will increase substantially in 2021 Initial supply will either be approved as a licensed vaccine or authorized for use under an EUA issued by the FDA Cold chain storage and handling requirements are likely to vary from refrigerated to ultracold frozen Two doses, separated by ≥21 or 28 days, will be needed for immunity for most COVID-19 vaccines




Texas Department of State Health Services

### **COVID-19 Vaccine Updates**

Phase III Vaccine Candidates	Technology Platform	Storage & Handling	Dose (Intramuscular Injection)	
Pfizer	m-RNA	Ultra-low frozen: 6mos Refrigerated: 5 days	2 (0, 21 days)	
moderna	m-RNA	Frozen: 6mos Refrigerated: 30 days	2 (0, 28 days)	
AstraZeneca ONFORD	Viral Vector (Non-Replicating)	Refrigerated: 6mos	2 (0, 28 days)	
Janssen PRARMACEUTICAL COMPANIES OF Solution St. March	Viral Vector (Non-Replicating)	Refrigerated: 6mos	1	

Phase III Vaccine Candidates	Technology Platform	Efficacy & Safety			Regulatory Status
		Study Design	Interim Analysis	Completion of Primary Endpoint	Status
Pfizer	m-RNA	<ul> <li>N=44,000</li> <li>≥ 12 yrs</li> <li>Randomization (1:1)</li> <li>Placebo vs. Vaccine</li> <li>(Saline vs. 30 µg)</li> <li>2 doses (0, 21 days)</li> </ul>	• 90% effectiveness (94 cases)	<ul> <li>95% vaccine efficacy (162 placebo vs. 8 vaccine)</li> <li>30 severe case (30 placebo vs. 0 vaccine)</li> <li>Consistent efficacy across age, gender, race/ethnicity</li> <li>No serious adverse reported to date</li> </ul>	EUA Filed
moderna	m-RNA	<ul> <li>N=30,000</li> <li>≥ 18 yrs</li> <li>Randomization (1:1)</li> <li>Placebo vs. Vaccine</li> <li>(Saline vs. 100 μg)</li> <li>2 doses (0, 28 days)</li> </ul>	<ul> <li>94.5% vaccine efficacy (90 placebo vs. 5 vaccine)</li> <li>11 severe case (11 placebo vs. 0 vaccine)</li> <li>16% adults ages &gt;65 yrs</li> <li>21% diverse population</li> <li>No serious adverse reported to date Grade 3 (&gt;2%): Fatigue, myalgia, arthralgia, headache, pain, &amp; redness at injection site</li> </ul>	94.1% vaccine efficacy (185 cases in placebo vs. 11 vaccine)     11 severe case (11 placebo vs. 0 vaccine)     17% adults ages >65 yrs     21% diverse population     1 death in the placebo group	EUA Filed
AstraZeneca OXFORD	Replicating)	UK Study  • N=12,390  • ≥ 18 yrs  • 1 Dose vs. 2 Doses vs. MenACWY  Brazil Study  • N=10,300  • ≥ 18 yrs  • 2 does vaccine vs. MenACWY/Saline	• 90% vaccine efficacy (half dose/full dose (5x10 <sup>10</sup> vp) with n=2,741 • 62% vaccine efficacy (full dose/full dose (n=8,895) • Combined efficacy of 70% (131 COVID-19 cases) • No serious adverse events have been reported thus far		
Janssen	Viral Vector (Non- Replicating)	<ul> <li>N=60,000</li> <li>≥ 18 yrs</li> <li>Randomization (1:1)</li> <li>Placebo vs. Vaccine (Saline vs. 5×10¹⁰ vp)</li> <li>1 doses</li> </ul>			



#### **MODERNA**

Dec. 17 → Dec. 18-21 → Dec. 18-21

Dec. 21-23

Vaccination



VRBPAC Open Session Meeting

FDA Reviews all the Data

EUA

CDC ACIP Calls an Immediate Meeting

Recommendations



BLA (Biologics Licensure Application) EUA (Emergency Use Authorization)

EA (Expanded Access)

### **COVID-19 Vaccine Safety Monitoring**

- Vaccine Adverse Event Reporting System (VAERS)
- V-safe



Texas Department of State
Health Services





#### Vaccine Adverse Event Reporting System

Co-managed by CDC and FDA

http://vaers.hhs.gov



VAERS is the nation's frontline system for monitoring vaccine safety

### **V-safe** | after vaccination health checker



V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after someone receives a COVID-19 vaccination.



Vaccine recipients can quickly tell the CDC if they have any side effects. The CDC may follow up with them by phone to get more information.



**V-safe** will also remind them to get their second COVID-19 vaccine dose, if needed.



Use your smartphone to tell CDC about any side effects after getting the COVID-19 vaccine. You'll also get reminders if you need a second vaccine dose.



### **V-safe** | after vaccination health checker

#### How long do v-safe check-ins last?

- During the first week after you get your vaccine, *v-safe* will send you a text message each day to ask how you are doing.
- Then you will get check-in messages once a week for up to 5 weeks.
- The questions v-safe asks should take less than 5 minutes to answer.
- If you need a second dose of vaccine, v-safe will provide a new 6-week check-in process so you can share your second-dose vaccine experience as well.
- You'll also receive check-ins 3, 6, and 12 months after your final dose of vaccine.



Use your smartphone
to tell CDC about
any side effects after
getting the COVID-19
vaccine. You'll also get
reminders if you need a
second vaccine dose.



### **V-safe** | provider role

- Give patients a v-safe information sheet at the time of vaccination
- Encourage them to enroll and fill out the surveys when prompted

https://vsafe.cdc.gov/

Get vaccinated. Get your smartphone. Get started with v-safe. Use your smartphone to tell CDC about any side effects after getting v-safe the COVID-19 vaccine. after vaccination You'll also get reminders if you need a second vaccine dose. When you get your about getting started Learn more about **v-safe** www.cdc.gov/vsafe

v-safe info poster



v-safe info sheets

# REMINDER

The information presented today is based on CDC's recent guidance and MAY change.

December 07, 2020